ACC/AHA 2026 Cholesterol Guideline Overhaul: Universal LDL <100, Very-High Risk <55, the Lower-for-Longer Era

The largest cardiovascular preventive medicine guideline overhaul in 8 years was just released. The 2026 dyslipidemia guideline jointly published by ACC (American College of Cardiology), AHA (American Heart Association), and 11 societies (Circulation 2026.3) retires the 2018 ACC/AHA guideline and sets a new standard. Core changes: universal LDL <100 mg/dL target (primary prevention), LDL <55 mg/dL (very high risk secondary prevention), and the new principle “lower for longer” (lower, longer = reduced cumulative cardiovascular risk).

4 Core Changes

1. Stronger LDL targets: from “100~130 recommended” to “<100 universal.” Average LDL of 50+ women around 130 mg/dL → almost all patients enter drug indication.

2. Earlier initiation: from “start after high cholesterol diagnosis” to “early start when risk factors accumulate.” Drug consideration from 30s~40s in family history, chronic kidney disease, accelerated menopause, LDL 160+.

3. Clear ladder steps:

   • Stage 1: statin (maximally tolerated dose)
   • Stage 2: add ezetimibe (Zetia)
   • Stage 3: PCSK9 inhibitor (evolocumab/Repatha, alirocumab/Praluent) or inclisiran (Leqvio)
   • Stage 4: add bempedoic acid in some patients

4. apoB measurement integration: in patients with normal LDL but many small LDL particles, apoB is more accurate risk marker.

Clinical Meaning in Women

Women’s cholesterol·cardiovascular circuit specificity:

• Pre-menopause: estrogen protective effect, naturally low LDL, high HDL
• Within 5 years post-menopause: natural LDL +1020 mg/dL, HDL -510 mg/dL. Cholesterol changes despite same diet·exercise
• 50+ women’s cardiovascular risk: approaches male levels. But lower diagnosis·treatment rates in women
• Co-occurring autoimmunity: rheumatoid arthritis, SLE, hypothyroidism patients have accelerated cardiovascular risk. New guideline recommends more aggressive LDL management

Drug Options

Statins (1st line):

• Rosuvastatin (Crestor), atorvastatin (Lipitor), simvastatin (Zocor)
• LDL 30~50% reduction
• Side effects: myalgia (5~10%), partial liver enzyme rise, rare rhabdomyolysis

Ezetimibe (2nd line):

• Blocks intestinal cholesterol absorption
• Alone LDL 15~20% reduction; statin + ezetimibe 65% reduction
• Few side effects

PCSK9 inhibitors (3rd line):

• Evolocumab (Repatha) 140mg every 2 weeks, alirocumab (Praluent) 75-150mg every 2 weeks subcutaneous
• Alone LDL 50~60% reduction; statin + PCSK9 75% reduction
• 15~20% cardiovascular event reduction in FOURIER, ODYSSEY trials
• Very few side effects, expensive

Inclisiran (Leqvio):

• siRNA-based PCSK9 inhibition (different mechanism)
• Subcutaneous injection every 6 months (initial 0, 3 months, then 6 months)
• LDL 50% reduction, very good adherence
• Cardiovascular event data pending in ORION-4 trial (2026~2027)
• Very expensive

Bempedoic acid (Nexletol):

• Alternative for statin-intolerant patients
• Alone LDL 17% reduction
• Some increase in gout·kidney stone risk

Korean Clinical Application

Korea is also likely to rapidly adopt the 2026 guideline. Korean women’s cardiovascular data:

• Average LDL in 50s women: about 125 mg/dL (less than 30% reach <100 target)
• Accelerated LDL increase post-menopause
• Low diagnosis·treatment rates for familial hypercholesterolemia (FH)

Under the new guideline:

• Most 50+ women enter drug indication
• Sharp increase in statin prescription expected
• Increased PCSK9·inclisiran consideration in family history + accelerated menopause patients
• Out-of-pocket PCSK9·inclisiran costs as adoption barrier (₩500,000–1,000,000/month)

Natural Matrix Concurrent Action

Drugs alone struggle to reach LDL targets. Concurrent matrix:

• Diet: Mediterranean, DASH. Saturated fat <6% calories, avoid trans fats
• Fiber 25~35g/day: especially soluble (oats, barley, beans, apples). LDL 5~10% additional reduction
• Omega-3 1,000~2,000mg/day: TG 20~30% reduction
• Sterols·stanols (plant): margarine·yogurt form 2g/day → LDL 10% reduction
• Exercise: 150 min/week moderate. HDL 5% increase, TG decrease
• Weight 5~10% loss: LDL 5~10% reduction
• No smoking: HDL recovery

Tracking Standards

• 6 weeks~3 months: LDL recheck after statin start
• 6 months~1 year: annual LDL + apoB after stabilization
• Liver enzymes·CK: at statin start + 6 weeks
• HbA1c: statins slightly increase diabetes risk (5~10%)

Core message: 50+ women are directly impacted by the new guideline. Like 25(OH)D, LDL·apoB also need baseline measurement + target decision + 6-month remeasurement matrix as the lifetime cardiovascular circuit foundation.